R Stock Recent News

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN® the highest possible recommendation (Grade I, A,1) via their practice guidelines.

The documentary, from Bad Robot, Glen Powell's Barnstorm Productions, Zipper Bros Films, IMAX Entertainment and Dolphin Entertainment reached over $2 million at the box office and was #1 on Prime Video when it was first released last summer MIAMI, FL / ACCESS Newswire / January 16, 2025 / The Blue Angels have been enthralling people across the country and around the globe for more than 75 years. IMAX Entertainment and Dolphin Entertainment (NASDAQ:DLPN) proudly present a thrilling new 3D version of the documentary "The Blue Angels" taking audiences soaring with the Navy's elite Flight Demonstration Squadron.

HALIFAX, NS / ACCESSWIRE / January 14, 2025 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today the approval from Health Canada for its Reveal®Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and high-quality result to be used in any health care setting.

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®. The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / General Enterprise Ventures, Inc. (OTC PINK:GEVI), a pioneer in the future of sustainable fire protection solutions, and its subsidiary, Mighty Fire Breaker®, LLC (MFB), extends their deepest sympathies to those affected by the recent Los Angeles wildfires. In response, we are launching a charitable initiative to support the impacted communities beginning with the donation of our patented, EPA-certified fire inhibitor, CitroTech®, to homeowners in high-risk areas, providing enhanced protection against future fire threats.

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R), a leader in supply chain, dedicated transportation, and fleet management solutions, expects to issue its fourth quarter 2024 results at approximately 7:00 a.m. Eastern Time on Wednesday, February 12, 2025. The company will also host a conference call at 11 a.m. Eastern Time on the same day. The call will be webcast live and a replay will be available. Details for the call include: When: Wednesday, February 12, 2025, from 11:00 a.m. to 12:00.

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis. The upcoming trials will be led by REACH Nexus at the MAP Centre for Urban Health Solutions at St. Michael's Hospital (Unity Health Toronto) with funding from the Canadian Institute of Health Research (CIHR) and Indigenous Services Canada (ISC).

Ryder System's shares have surged significantly, outperforming the S&P 500, and remain attractively priced, justifying a continued 'buy' rating. The company's revenue and operating revenue have shown consistent growth, driven by its Fleet Management, Supply Chain, and Dedicated Transportation Solutions segments. Despite mixed profitability, Ryder's operating cash flow and EBITDA have generally increased, with promising forecasts for 2024.

LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced that Chief Financial Officer Kevin Williamson will host one-on-one investor meetings in San Francisco, CA during the week of January 13th in accordance with the 43rd Annual J.P. Morgan Healthcare Conference.

License Agreement Expands Zomedica's Portfolio with Revolutionary Hemostatic Technology ANN ARBOR, MI / ACCESSWIRE / January 7, 2025 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it had entered into a license and supply agreement with Cresilon, Inc. to market and sell the Vetigel® hemostatic gel product line on an exclusive basis in the United States and on a non-exclusive basis outside the United States. Under the terms of the agreement, Zomedica will assume responsibility for supplying U.S. customers and will collaborate with Cresilon to support customers outside the U.S. This partnership enables Zomedica to further its mission of delivering innovative solutions that enhance patient care and operational efficiency for veterinary practitioners.